Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ShotCAR CD19
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
ShotCAR CD19 is a non-viral chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of hematologic malignancies. Developed using Hauul Bio's proprietary ShotCAR platform, the therapy utilizes a recombinant fusion protein CAR system. Unlike traditional CAR-T therapies that rely on viral vectors for gene transduction, the ShotCAR platform independently expresses and purifies recombinant CAR proteins and introduces them directly into immune cells. This non-viral approach is designed to simplify the manufacturing process, reduce costs, and improve safety by avoiding viral integration. ShotCAR CD19 specifically targets CD19-positive malignant cells to induce their destruction. The drug is currently in the discovery/research stage of development.
02
Targets
Beyond the preview
Go deeper on ShotCAR CD19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ShotCAR CD19.